Stem cell quest

Area of Science:

• Hematology
• Cancer Biology
• Molecular Medicine

Background:

• Chronic Myeloid Leukaemia (CML) is a hematologic malignancy characterized by a specific genetic alteration in over 95% of patients.
• Tyrosine kinase inhibitors (TKIs) have significantly improved patient outcomes since their introduction in 2000.
• Despite TKI efficacy, drug resistance remains a challenge, and CML is typically controlled rather than eradicated.

Purpose of the Study:

• To identify the specific leukaemic stem cell sub-population responsible for CML propagation.
• To explore novel therapeutic targets beyond current TKI treatments.

Main Methods:

• Analysis of leukaemic stem cell populations in CML patients.
• Identification of specific cell surface markers associated with disease propagation.

Main Results:

• A distinct sub-population of leukaemic stem cells driving CML has been defined.
• CD26 has been identified as a specific target on these malignant stem cells.

Conclusions:

• Targeting CD26 presents a promising new strategy for achieving a true curative therapy for CML.
• This discovery could lead to more effective and potentially curative treatments for CML, overcoming current therapeutic limitations.